Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Ranibizumab Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Single-use prefilled syringe
  • 1.4.3 Single-use glass vial
• 1.5 Market by Application
  • 1.5.1 Global Ranibizumab Market Share by Application (2014-2025)
  • 1.5.2 wAMD
  • 1.5.3 Diabetic Retinopathy (DR)
  • 1.5.4 Diabetic Macular Edema (DME)
  • 1.5.5 mCNV
  • 1.5.6 RVO
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Ranibizumab Market Size
• 2.2 Ranibizumab Growth Trends by Regions
  • 2.2.1 Ranibizumab Market Size by Regions (2014-2025)
  • 2.2.2 Ranibizumab Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Ranibizumab Market Size by Manufacturers
  • 3.1.1 Global Ranibizumab Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Ranibizumab Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Ranibizumab Market Concentration Ratio (CR5 and HHI)
• 3.2 Ranibizumab Key Players Head office and Area Served
• 3.3 Key Players Ranibizumab Product/Solution/Service
• 3.4 Date of Enter into Ranibizumab Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Ranibizumab Market Size by Type (2014-2019)
• 4.2 Global Ranibizumab Market Size by Application (2014-2019)

5 United States

• 5.1 United States Ranibizumab Market Size (2014-2019)
• 5.2 Ranibizumab Key Players in United States
• 5.3 United States Ranibizumab Market Size by Type
• 5.4 United States Ranibizumab Market Size by Application

6 Europe

• 6.1 Europe Ranibizumab Market Size (2014-2019)
• 6.2 Ranibizumab Key Players in Europe
• 6.3 Europe Ranibizumab Market Size by Type
• 6.4 Europe Ranibizumab Market Size by Application

7 China

• 7.1 China Ranibizumab Market Size (2014-2019)
• 7.2 Ranibizumab Key Players in China
• 7.3 China Ranibizumab Market Size by Type
• 7.4 China Ranibizumab Market Size by Application

8 Japan

• 8.1 Japan Ranibizumab Market Size (2014-2019)
• 8.2 Ranibizumab Key Players in Japan
• 8.3 Japan Ranibizumab Market Size by Type
• 8.4 Japan Ranibizumab Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Ranibizumab Market Size (2014-2019)
• 9.2 Ranibizumab Key Players in Southeast Asia
• 9.3 Southeast Asia Ranibizumab Market Size by Type
• 9.4 Southeast Asia Ranibizumab Market Size by Application

10 India

• 10.1 India Ranibizumab Market Size (2014-2019)
• 10.2 Ranibizumab Key Players in India
• 10.3 India Ranibizumab Market Size by Type
• 10.4 India Ranibizumab Market Size by Application

11 Central & South America

• 11.1 Central & South America Ranibizumab Market Size (2014-2019)
• 11.2 Ranibizumab Key Players in Central & South America
• 11.3 Central & South America Ranibizumab Market Size by Type
• 11.4 Central & South America Ranibizumab Market Size by Application

12 International Players Profiles

• 12.1 Genentech
  • 12.1.1 Genentech Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Ranibizumab Introduction
  • 12.1.4 Genentech Revenue in Ranibizumab Business (2014-2019)
  • 12.1.5 Genentech Recent Development
• 12.2 Novartis
  • 12.2.1 Novartis Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Ranibizumab Introduction
  • 12.2.4 Novartis Revenue in Ranibizumab Business (2014-2019)
  • 12.2.5 Novartis Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
In 2018, the global Ranibizumab market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Ranibizumab status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Ranibizumab development in United States, Europe and China.

The key players covered in this study
Genentech
Novartis
...

Market segment by Type, the product can be split into
Single-use prefilled syringe
Single-use glass vial

Market segment by Application, split into
wAMD
Diabetic Retinopathy (DR)
Diabetic Macular Edema (DME)
mCNV
RVO

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Ranibizumab status, future forecast, growth opportunity, key market and key players.
To present the Ranibizumab development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Ranibizumab are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.